Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer

Liang, Siying; Lin, Xu; Zhang, Dongsheng; Wu, Zhenjun

doi:10.5152/tjg.2016.15375

Cited by 56 publications

(31 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The authors showed that the group receiving probiotic treatment (Bifidobacterium) and PPI had 19.0% SIBO-positive patients, whereas the group that was administered placebo and PPI showed 74.6% SIBO-positive patients. 20 SIBO prevalence reported by Liang et al 20 is higher compared to our study both in placebo and probiotics lot (56.2% and 6.2% respectively), but this Chinese research was conducted on adults patients with GI malignancies, that might increase the rate of intestinal dysbiosis.…”

Section: Discussioncontrasting

confidence: 66%

“…The clinical symptoms in the study by Liang et al 20 were much diminished in the probiotics group, and this difference reached statistical significance on comparison with the placebo arm of the study (P < 0.05). These results are similar to our report.…”

Section: Discussionmentioning

confidence: 81%

“…Liang et al 20 reported that 116 of 200 patients with GI malignancies (58.0%) were long-term PPI users and of these, 86 (74.1%) were positive for SIBO. The authors showed that the group receiving probiotic treatment (Bifidobacterium) and PPI had 19.0% SIBO-positive patients, whereas the group that was administered placebo and PPI showed 74.6% SIBO-positive patients.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?

Belei

Olariu

Dobrescu

et al. 2018

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/Aims Gastroesophageal reflux disease (GERD) is a frequent condition diagnosed in children and treated with proton pump inhibitors (PPI). Long-term PPI administration can alter intestinal bacterial population by suppressing the gastric acid barrier and may cause diarrhea. The aim of this study is to evaluate the prevalence of small intestinal bacterial overgrowth assessed by glucose hydrogen breath test among children that received 12 weeks of PPI with or without probiotics ( Lactobacillus reuteri DSM 17938) associated, compared to controls. Methods Glucose hydrogen breath test was performed before PPI treatment and after 12 weeks of PPI treatment to 128 consecutive children with GERD (1–18 years old) and a control group (120 healthy children). The children with GERD were randomized into 2 groups: placebo group (64 who received PPI and placebo for 12 weeks) and probiotics group (64 who received PPI and probiotics for 12 weeks). Results After 12 weeks of treatment, dysbiosis was detected among 56.2% of children from placebo group (36/64), compared to 6.2% of children from the probiotics group (4/64, P < 0.001). Bacterial overgrowth was detected in 5% of controls (6/120). Probiotics group had a lower prevalence of dysbiosis, similar to controls ( P = 0.740). Conclusion Probiotics administration decreased the rate of dysbiosis among children treated with PPI.

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Discussionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?

Belei

Olariu

Dobrescu

et al. 2018

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…Notably, another probiotic, Lactobacillus casei strain BL23 not only inhibited CRC in mice, but also counteracted gut dysbiosis induced by CRC . Additionally, recent clinical studies established that oral Bifidobacterium triple viable probiotics could improve gut dysbiosis and combat small intestinal bacterial overgrowth in CRC patients …”

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Casupporting

confidence: 68%

“…88 Additionally, recent clinical studies established that oral Bifidobacterium triple viable probiotics could improve gut dysbiosis and combat small intestinal bacterial overgrowth in CRC patients. 89,90 Our team identified the role of intestinal dysbiosis induced by deoxycholic acid (a carcinogenic secondary bile acid) in the development of CRC. We found that the transfer of feces from deoxycholic acid-treated mice increased intestinal tumor development compared to untreated donor.…”

Section: Fmt For Digestive System Cancersmentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

239

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

Effects of Probiotics on Intestinal Failure–Associated Liver Disease in Adult Patients Receiving Prolonged Parenteral Support: A Tertiary Care Center Experience

et al. 2019

View full text Add to dashboard Cite

Background: It has been hypothesized that dysbiosis plays a significant role in the pathogenesis of intestinal failure-associated liver disease (IFALD). Therefore, we aimed to investigate the effect of probiotics on IFALD in patients receiving parenteral support, namely home parenteral nutrition (HPN) and home intravenous fluids (HIVFs). Methods: We retrospectively reviewed charts of patients with intestinal failure who received HPN or HIVF for >2 weeks at our tertiary center between January 2005 and August 2016. We excluded patients <18 years of age, patients with other causes of liver disease, patients who used probiotics for <30 days, patients with <6 months' follow-up, and those who had long-term antibiotic use (>30 days). Bivariable and multivariable logistic regression analyses were used in this study. Results: A total of 282 patients who received parenteral support were included. Eightyfive percent of our sample received PN. A total of 78 (27.7%) patients used probiotics. The prevalence of IFALD in patients who used probiotics was 35.9% vs 54.4% in patients who did not use probiotics, P = .005. In multivariable analysis, only small-bowel length of 10-90 cm and HPN use showed a significant impact on IFALD, odds ratio (OR) = 4.394 (95% confidence interval [CI], 1.635-11.814; P = .003) and OR = 4.502 (95% CI 1.412-14.351; P = .011), respectively. Conclusion: Our study revealed that the prevalence of IFALD was comparable among the probiotic users and nonusers. Only small bowel length of 1090 cm and HPN use showed a significant impact on IFALD.

show abstract

Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer

Cited by 56 publications

References 21 publications

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?

Is It Useful to Administer Probiotics Together With Proton Pump Inhibitors in Children With Gastroesophageal Reflux?

Fecal microbiota transplantation in cancer management: Current status and perspectives

Effects of Probiotics on Intestinal Failure–Associated Liver Disease in Adult Patients Receiving Prolonged Parenteral Support: A Tertiary Care Center Experience

Contact Info

Product

Resources

About